Dianthus Therapeutics (Dianthus Therapeutics) Cash-to-Debt : 758.62 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Dianthus Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 758.62.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Dianthus Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Dianthus Therapeutics's Cash-to-Debt or its related term are showing as below:

DNTH' s Cash-to-Debt Range Over the Past 10 Years
Min: 95.8 Med: 296.95 Max: No Debt
Current: 758.62

During the past 3 years, Dianthus Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 95.80. And the median was 296.95.

DNTH's Cash-to-Debt is ranked better than
86.82% of 1540 companies
in the Biotechnology industry
Industry Median: 6.485 vs DNTH: 758.62

Dianthus Therapeutics Cash-to-Debt Historical Data

The historical data trend for Dianthus Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Dianthus Therapeutics Cash-to-Debt Chart

Dianthus Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

95.80

296.95

Dianthus Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial			95.80	N/A	283.39	296.95	758.62

Competitive Comparison of Dianthus Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Dianthus Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dianthus Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Dianthus Therapeutics's Cash-to-Debt falls into.

Dianthus Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Dianthus Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	173.718	/	(0.417	+	0.168)
	=	296.95

Dianthus Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	377.036	/	(0.4	+	0.097)
	=	758.62

Dianthus Therapeutics (NAS:DNTH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Dianthus Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

87E:Germany

Address

7 Times Square, 43rd Floor, New York, NY, USA, 10036

Website

https://www.dianthustx.com

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines

From GuruFocus

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

By GuruFocus Research • 09-29-2023

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

By GuruFocus Research • 09-14-2023